Top 5 Biotechnology Startup Investors in Isle of Man (June 2026)

Portfolio highlights

• Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Portfolio highlights

• OncoSenX — OncoSenX is a developer of transient gene therapies designed for solid tumors. The company's therapy delivers plasmid DNA with a novel lipid nanoparticle that selectively kills cancerous cells based on their transcriptional activity, providing cancer patients, doctors and medical care professionals with a less invasive and more preciseintervention for this complex and devastating disease.
• Netwealth — Netwealth provides expert investment management and tailored wealth planning solutions, helping you confidently achieve your financial goals.
• Repair Biotechnologies — Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling humanbeings to improve their health span through targeting the causes of age-related diseases and ageing itself.

Portfolio highlights

• Pharvaris — Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
• ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
• Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

Portfolio highlights

• LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
• MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
• Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

Portfolio highlights

• Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
• Serina Therapeutics — Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of smallmolecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy.
• Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.